## Joseph Menczer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8595585/publications.pdf

Version: 2024-02-01

51	1,246	15 h-index	35
papers	citations		g-index
51	51	51	1327
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma. Israel Medical Association Journal, 2018, 20, 213-216.	0.1	O
2	Is there a revision needed of the current $<$ scp $>$ FIGO $<$ /scp $>$ staging system?. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 1159-1161.	2.8	4
3	Hysterscopic Resection of Premalignant and Malignant Endometrial Polyps: Is it a Safe Alternative to Hysterectomy?. Journal of Minimally Invasive Gynecology, 2017, 24, 1200-1203.	0.6	15
4	Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. Archives of Gynecology and Obstetrics, 2017, 295, 9-15.	1.7	31
5	The optimal angle of the mediolateral episiotomy at crowning of the head during labor. International Urogynecology Journal, 2017, 28, 1795-1799.	1.4	8
6	The Effect of Cyclooxygenase-2 Expression in Uterine Carcinosarcoma on Survival. International Journal of Gynecological Cancer, 2015, 25, 1415-1417.	2.5	2
7	Very late recurrence (after more than 20Âyears) of epithelial ovarian carcinoma: case report and literature review. Archives of Gynecology and Obstetrics, 2015, 291, 1199-1203.	1.7	9
8	Review of Recommended Treatment of Uterine Carcinosarcoma. Current Treatment Options in Oncology, 2015, 16, 53.	3.0	33
9	The Significance of Normal Pretreatment Levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma. Rambam Maimonides Medical Journal, 2015, 6, e0005.	1.0	14
10	Treatment Delay in Endometrial Cancer. Journal of Clinical Oncology, 2014, 32, 2113-2114.	1.6	4
11	CA125 expression in the tissue of uterine leiomyosarcoma. Israel Medical Association Journal, 2014, 16, 697-9.	0.1	8
12	Conservative fertility-sparing surgical treatment of invasive epithelial ovarian cancer: when is it acceptable?. Israel Medical Association Journal, 2013, 15, 116-20.	0.1	3
13	The effect of hysterectomy on survival of patients with borderline ovarian tumors. Gynecologic Oncology, 2012, 125, 372-375.	1.4	23
14	Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?. Journal of Gynecologic Oncology, 2011, 22, 183.	2.2	11
15	COX-2 Expression in Nonepithelial Ovarian Malignancies. International Journal of Gynecological Pathology, 2011, 30, 41-45.	1.4	1
16	Selected demographic characteristics of Israeli Jewish women with high-grade cervical intraepithelial neoplasia (CIN3): a population-based study. Archives of Gynecology and Obstetrics, 2011, 283, 329-333.	1.7	5
17	A population-based study of selected demographic characteristics of Israeli-Jewish women with cervical squamous cell carcinoma. Archives of Gynecology and Obstetrics, 2011, 283, 629-633.	1.7	8
18	Reply: The role of neoadjuvant chemotherapy in ovarian cancer patients with extensive tumor burden. Journal of Gynecologic Oncology, 2011, 22, 300.	2.2	0

#	Article	IF	CITATIONS
19	Cervical neoplasia in Israeli Jewish women: characteristics in a low risk population. Israel Medical Association Journal, 2011, 13, 700-4.	0.1	3
20	COXâ€2 expression in uterine carcinosarcoma. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 120-125.	2.8	14
21	The effect of symptom duration in epithelial ovarian cancer on prognostic factors. Archives of Gynecology and Obstetrics, 2009, 279, 797-801.	1.7	9
22	Incidence trends of cervical adenocarcinoma in Israeli Jewish women. A population-based study. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 280-285.	2.8	5
23	Cox-2 expression in ovarian malignancies. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 146, 129-132.	1.1	15
24	Incidence Rates of Cervical Carcinoma Among First- and Second-Generation Women of North African Origin in Israel. International Journal of Gynecological Cancer, 2009, 19, 1606-1609.	2.5	10
25	Risk Factor Proportions in Israeli Patients With Cervical Intraepithelial Neoplasia 3 and Invasive Squamous Cell Carcinoma. Journal of Lower Genital Tract Disease, 2008, 12, 220-223.	1.9	4
26	Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia. Gynecologic Oncology, 2007, 104, 675-679.	1.4	7
27	The human papillomavirus vaccine and its relevance in Israel. Israel Medical Association Journal, 2007, 9, 546-9.	0.1	1
28	Endometrial endometrioid carcinoma: A glimpse at the natural course. American Journal of Obstetrics and Gynecology, 2006, 195, 454-457.	1.3	11
29	Primary peritoneal carcinoma—Uterine involvement and hysterectomy. Gynecologic Oncology, 2006, 100, 565-569.	1.4	6
30	Follow-up of ovarian and primary peritoneal carcinoma: The value of physical examination in patients with pretreatment elevated CA125 levels. Gynecologic Oncology, 2006, 103, 137-140.	1.4	23
31	Expression of c-kit in uterine carcinosarcoma. Gynecologic Oncology, 2005, 96, 210-215.	1.4	23
32	A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecologic Oncology, 2005, 97, 166-170.	1.4	76
33	Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. American Journal of Obstetrics and Gynecology, 2004, 190, 1039-1045.	1.3	69
34	The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved?. Israel Medical Association Journal, 2003, 5, 120-3.	0.1	14
35	Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a <i>BRCA1</i> or <i>BRCA2</i> Mutation. New England Journal of Medicine, 2001, 345, 235-240.	27.0	370
36	Metastatic Trophoblastic Disease Following Partial Hydatidiform Mole: Case Report and Literature Review. Gynecologic Oncology, 1999, 74, 304-307.	1.4	28

#	Article	IF	CITATIONS
37	Primary Peritoneal Serous Papillary Carcinoma: A Study of 25 Cases and Comparison with Stage Ill–IV Ovarian Papillary Serous Carcinoma. Gynecologic Oncology, 1996, 60, 393-396.	1.4	90
38	The effect of diagnosis and treatment delay on prognostic factors and survival in endometrial carcinoma. American Journal of Obstetrics and Gynecology, 1995, 173, 774-778.	1.3	35
39	Impaired binding properties of endothelin-1 receptors in human endometrial carcinoma tissue. Cancer, 1993, 72, 1955-1958.	4.1	8
40	Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission. Cancer, 1992, 70, 1956-1959.	4.1	15
41	Downregulation of specific protein carboxylmethyltransferase immunoreactivity in human endometrial carcinoma. Cancer, 1991, 68, 1742-1746.	4.1	1
42	Increased density of peripheral benzodiazepine-binding sites in ovarian carcinomas as compared with benign ovarian tumours and normal ovaries. Clinical Science, 1990, 78, 155-158.	4.3	100
43	Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after. Second-look laparotomy. Cancer, 1989, 63, 1509-1513.	4.1	24
44	High levels of protein carboxyl methyltransferase in well-differentiated human endometrial carcinoma. FEBS Letters, 1988, 228, 277-280.	2.8	3
45	Primary infertility in women exposed to diethylstilboestrol in utero. BJOG: an International Journal of Obstetrics and Gynaecology, 1986, 93, 503-507.	2.3	4
46	Primary infertility in women exposed to diethylstilboestrol in utero. BJOG: an International Journal of Obstetrics and Gynaecology, 1986, 93, 503-507.	2.3	11
47	Herpesvirus type 2 in adenocarcinoma of the uterine cervix: A possible association. Cancer, 1981, 48, 1497-1499.	4.1	9
48	Prospective Follow-Up of Patients with Hydatidiform Mole. Obstetrics and Gynecology, 1980, 55, 346-349.	2.4	14
49	Possible role of mumps virus in the etiology of ovarian cancer. Cancer, 1979, 43, 1375-1379.	4.1	33
50	Possible role of mumps virus in the etiology of ovarian cancer. , 1979, 43, 1375.		1
51	Adenocarcinoma of the uterine cervix in Jewish women. A distinct epidemiological entity. Cancer, 1978, 41, 2464-2467.	4.1	31